InnovAge Holding Corp. (NASDAQ:INNV – Get Free Report) COO Michael Anthony Scarbrough sold 33,000 shares of the company’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $4.90, for a total transaction of $161,700.00. Following the completion of the transaction, the chief operating officer owned 119,617 shares of the company’s stock, valued at $586,123.30. This trade represents a 21.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
InnovAge Stock Performance
InnovAge stock opened at $5.59 on Wednesday. InnovAge Holding Corp. has a 12-month low of $2.60 and a 12-month high of $6.26. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.17 and a quick ratio of 1.17. The company has a market capitalization of $758.45 million, a price-to-earnings ratio of -43.00 and a beta of 0.59. The firm’s fifty day moving average price is $5.07 and its 200 day moving average price is $4.27.
InnovAge (NASDAQ:INNV – Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.05. InnovAge had a negative return on equity of 7.02% and a negative net margin of 1.96%.The company had revenue of $236.11 million during the quarter, compared to the consensus estimate of $226.64 million. InnovAge has set its FY 2026 guidance at EPS. On average, research analysts forecast that InnovAge Holding Corp. will post -0.12 EPS for the current fiscal year.
Institutional Investors Weigh In On InnovAge
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of InnovAge in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of InnovAge to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, JPMorgan Chase & Co. began coverage on shares of InnovAge in a report on Thursday, September 18th. They issued an “underweight” rating and a $5.00 price target on the stock. Two investment analysts have rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell” and a consensus price target of $5.00.
Get Our Latest Stock Analysis on INNV
InnovAge Company Profile
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management.
Read More
- Five stocks we like better than InnovAge
- Insider Trading – What You Need to Know
- What’s on the Thanksgiving Table? A Stock Pick for Every Course
- 3 Healthcare Dividend Stocks to Buy
- Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain
- Top Biotech Stocks: Exploring Innovation Opportunities
- Qualcomm’s Bulls Are Running Out of Room to Be Wrong
Receive News & Ratings for InnovAge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnovAge and related companies with MarketBeat.com's FREE daily email newsletter.
